Paul Kubelac
Overview
Explore the profile of Paul Kubelac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roman A, Brozba A, Necula A, Muntean D, Kubelac P, Fekete Z, et al.
Diagnostics (Basel)
. 2023 Dec;
13(23).
PMID: 38066786
This study aimed to assess the effectiveness of saline sealing in reducing the incidence of pneumothorax after a CT-guided lung biopsy. This was a retrospective case-control study of patients who...
2.
Cheeseman S, Levick B, Sopwith W, Fenton H, Nam E, Kim D, et al.
Front Oncol
. 2023 Feb;
13:1114435.
PMID: 36776297
Introduction: Much drug development and published analysis for epithelial ovarian cancer (EOC) focuses on early-line treatment. Full sequences of treatment from diagnosis to death and the impact of later lines...
3.
Tripac I, Agius J, Harasani K, Kubelac P, Stratan V, Tutuianu V, et al.
Chirurgia (Bucur)
. 2022 Dec;
117(6):689-697.
PMID: 36584061
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. In literature, there are discordant data regarding the therapeutic value of systematic lymphadenectomy whereas the importance of lymph...
4.
Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present
Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Ruhli F
J Ovarian Res
. 2022 Jun;
15(1):67.
PMID: 35659345
Ovarian cancer is composed of a complex system of cells best described by features such as clonal evolution, spatial and temporal genetic heterogeneity, and development of drug resistance, thus making...
5.
Schitcu V, Florea M, Marica N, Vlad I, Cojocaru I, Munteanu V, et al.
J BUON
. 2021 Jul;
26(3):964-969.
PMID: 34268960
Purpose: Salvage therapy represents a rescue therapy, given after the first line of treatment had failed.The purpose of this study was to review the outcomes of patients who underwent salvage...
6.
Yordanov A, Kostov S, Slavchev S, Strashilov S, Konsoulova A, Calleja-Agius J, et al.
Cancer Manag Res
. 2021 Jun;
13:4979-4986.
PMID: 34188551
Introduction: Historically, the incidence rate of cervical cancer (CC) in Eastern Europe and particularly in Bulgaria has constantly been higher than that in the other European countries. Adenosquamous carcinoma (ASC)...
7.
Gaia-Oltean A, Pop L, Cojocneanu R, Buse M, Zimta A, Kubelac P, et al.
Am J Cancer Res
. 2021 May;
11(4):1754-1769.
PMID: 33948387
Ovarian cancer is one of the most common cancers worldwide, and is associated with a prior diagnosis of endometriosis in several cases. Our aim was to correlate genetic and methylation...
8.
Kubelac P, Braicu C, Raduly L, Chiroi P, Nutu A, Cojocneanu R, et al.
Diagnostics (Basel)
. 2021 Mar;
11(2).
PMID: 33669647
The Hippo signaling pathway, one of the most conserved in humans, controlling dimensions of organs and tumor growth, is frequently deregulated in several human malignancies, including ovarian cancer (OC). The...
9.
Di Fiore R, Suleiman S, Ellul B, OToole S, Savona-Ventura C, Felix A, et al.
Cancers (Basel)
. 2021 Jan;
13(3).
PMID: 33514073
More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed...
10.
Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, et al.
J BUON
. 2020 Aug;
25(3):1658-1663.
PMID: 32862619
Purpose: The purpose of this study was to evaluate the predictive performance of OncoOVARIAN Dx algorithm, which takes into account tumor markers (beta HCG, CA 19.9, CEA, AFP, CA 125,...